Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector

Keizo Kasono, Jerry L. Blackwell, Joanne T. Douglas, Igor Dmitriev, Theresa V. Strong, Paul Reynolds, David A. Kropf, William R. Carroll, Glenn E. Peters, R. Pat Bucy, David T. Curiel, Victor Krasnykh

Research output: Contribution to journalArticle

129 Scopus citations

Abstract

In vivo cancer gene therapy approaches for squamous cell carcinoma of the head and neck (SCCHN) based on adenoviral vector-mediated gene delivery have been limited by the suboptimal efficacy of gene transfer to tumor cells. We hypothesized that this issue was due to deficiency of the primary adenoviral receptor, the coxsackie-adenovirus receptor (CAR), on the tumor targets. Studies of CAR levels on SCCHN cell lines confirmed that their relative refractoriness to the adenoviral vector was based on this deficiency. To circumvent this deficiency, we applied an adenoviral vector targeted to a tumor cell marker characteristic of SCCHN. In this regard, integrins of the α2β1 and α3β1 class are frequently overexpressed in SCCHN. Furthermore, these integrins recognize the RGD peptide motif. On this basis, we applied an adenoviral vector genetically modified to contain such a peptide within the HI loop of the fiber protein as a means to alter viral tropism. Studies confirmed that the CAR-independent gene delivery achieved via this strategy allowed enhanced gene transfer efficiencies to SCCHN tumor cells. Importantly, this strategy could achieve preferential augmentation of gene transfer in tumor cells compared with normal cells. The ability to achieve enhanced and specific gene transfer to tumor cells via adenoviral vectors has important implications for gene therapy strategies for SCCHN and for other neoplasms in general.

Original languageEnglish
Pages (from-to)2571-2579
Number of pages9
JournalClinical Cancer Research
Volume5
Issue number9
StatePublished - Sep 1 1999
Externally publishedYes

Fingerprint Dive into the research topics of 'Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector'. Together they form a unique fingerprint.

  • Cite this

    Kasono, K., Blackwell, J. L., Douglas, J. T., Dmitriev, I., Strong, T. V., Reynolds, P., Kropf, D. A., Carroll, W. R., Peters, G. E., Bucy, R. P., Curiel, D. T., & Krasnykh, V. (1999). Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clinical Cancer Research, 5(9), 2571-2579.